235 related articles for article (PubMed ID: 10798808)
21. Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M; Shigematsu N; Kubo A
Brachytherapy; 2007; 6(4):246-53. PubMed ID: 17959425
[TBL] [Abstract][Full Text] [Related]
22. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
23. Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients.
Reed DR; Wallner KE; Narayanan S; Sutlief SG; Ford EC; Cho PS
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):301-7. PubMed ID: 16111600
[TBL] [Abstract][Full Text] [Related]
24. Greater postimplant swelling in small-volume prostate glands: implications for dosimetry, treatment planning, and operating room technique.
Chung E; Stenmark MH; Evans C; Narayana V; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1944-8. PubMed ID: 21640498
[TBL] [Abstract][Full Text] [Related]
25. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.
Yue N; Dicker AP; Corn BW; Nath R; Waterman FM
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):447-54. PubMed ID: 10030274
[TBL] [Abstract][Full Text] [Related]
26. The impact of edema on planning 125I and 103Pd prostate implants.
Yue N; Dicker AP; Nath R; Waterman FM
Med Phys; 1999 May; 26(5):763-7. PubMed ID: 10360539
[TBL] [Abstract][Full Text] [Related]
27. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Walbert HL
Radiat Oncol Investig; 1998; 6(4):182-90. PubMed ID: 9727878
[TBL] [Abstract][Full Text] [Related]
28. Prostatic conformal brachytherapy: 125I/103Pd postoperative dosimetric analysis.
Merrick GS; Butler WM; Dorsey AT; Walbert HL
Radiat Oncol Investig; 1997; 5(6):305-13. PubMed ID: 9436248
[TBL] [Abstract][Full Text] [Related]
29. Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion.
Tanaka O; Hayashi S; Matsuo M; Nakano M; Uno H; Ohtakara K; Miyoshi T; Deguchi T; Hoshi H
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):614-8. PubMed ID: 17869675
[TBL] [Abstract][Full Text] [Related]
30. First report of transperineal polyethylene glycol hydrogel spacer use to curtail rectal radiation dose after permanent iodine-125 prostate brachytherapy.
Beydoun N; Bucci JA; Chin YS; Malouf D; Enari E; Painter SD
Brachytherapy; 2013; 12(4):368-74. PubMed ID: 23453682
[TBL] [Abstract][Full Text] [Related]
31. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique.
Zelefsky MJ; Yamada Y; Cohen G; Venkatraman ES; Fung AY; Furhang E; Silvern D; Zaider M
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):601-8. PubMed ID: 10974481
[TBL] [Abstract][Full Text] [Related]
32. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Solc Z; Huff W; Cantor A; Steele J; Webster C; Donohue M
Tech Urol; 2000 Jun; 6(2):128-34. PubMed ID: 10798814
[TBL] [Abstract][Full Text] [Related]
33. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
34. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.
Ellis RJ; Zhou H; Kaminsky DA; Fu P; Kim EY; Sodee DB; Colussi V; Spirnak JP; Whalen CC; Resnick MI
Brachytherapy; 2007; 6(2):149-56. PubMed ID: 17434109
[TBL] [Abstract][Full Text] [Related]
35. Iodine-125 thin seeds decrease prostate swelling during transperineal interstitial permanent prostate brachytherapy.
Beydoun N; Bucci JA; Chin YS; Malouf D
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):109-16. PubMed ID: 24529064
[TBL] [Abstract][Full Text] [Related]
36. [Changes of edema associated with I-125 prostate brachytherapy].
Aoki M; Miki K; Takahashi H; Takagi S; Fukuda I; Honda C; Kobayashi M; Egawa S; Kanehira C
Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Oct; 65(4):411-8. PubMed ID: 16334395
[TBL] [Abstract][Full Text] [Related]
37. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
[TBL] [Abstract][Full Text] [Related]
38. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer.
Prestidge BR; Hoak DC; Grimm PD; Ragde H; Cavanagh W; Blasko JC
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):31-9. PubMed ID: 9054874
[TBL] [Abstract][Full Text] [Related]
39. Prostate volume changes during permanent seed brachytherapy: an analysis of intra-operative variations, predictive factors and clinical implication.
Chira C; Delouya G; Larrivée S; Carrier JF; Taussky D
Radiat Oncol; 2013 Jul; 8():177. PubMed ID: 23837971
[TBL] [Abstract][Full Text] [Related]
40. [Permanent implant brachytherapy for early, organ-confined prostate cancer].
Agoston P; Major T; Fröhlich G; Baricza K; Szabó Z; Lövey J; Varjas G; Kásler M; Fodor J; Polgár C
Magy Onkol; 2011 Sep; 55(3):170-7. PubMed ID: 21918742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
